PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.
about
PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat.Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Treatment of hemophilia B: focus on recombinant factor IX.Preferential Interactions and the Effect of Protein PEGylation.Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugatesWhat is the future of PEGylated therapies?Molecular approaches for improved clotting factors for hemophilia.Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.Changing paradigm of prophylaxis with longer acting factor concentrates.Longer-acting clotting factor concentrates for hemophilia.New products for the treatment of haemophilia.PEGylated Cationic Serum Albumin for Boosting Retroviral Gene Transfer.Safety surveillance in haemophilia and allied disorders.Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.A close insight to factor VIII inhibitor in the congenital hemophilia A.Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.2017 Clinical trials update: Innovations in hemophilia therapy.The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study.Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.Current and emerging factor VIII replacement products for hemophilia A.Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.Managing haemophilia for life: 4th Haemophilia Global Summit.The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.Novel approaches to hemophilia therapy: successes and challenges.Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays.Novel therapies and current clinical progress in hemophilia A.Emerging therapies for hemophilia: controversies and unanswered questions.Practical aspects of extended half-life products for the treatment of haemophilia
P2860
Q27691352-A5C3B939-0013-4B9C-BEBC-C7E15502D560Q33552218-1736D862-DC12-4B70-BD49-7CDD808D13FEQ34045763-CD757DAF-24E9-478C-8E3C-56C55A641B6AQ34329068-BCF0F6C9-F553-443A-88A3-68BACB080B11Q35730064-760AE08E-7ACE-4538-BE28-D5E7385ADCC3Q36533097-4D4DA8E5-6333-4976-A493-ADCA9C6DC14CQ37006106-EEEA764E-E2CE-4C8B-B5AA-42B9EC26A707Q37334700-86D0CA08-E953-4B4E-954D-F13D7347409CQ38127745-21DB3FF7-8E35-4CFB-82A2-473E4621A89CQ38206858-4DE4C8A7-0169-49DE-AE94-E3B52EFD26CFQ38543283-B68329B2-B7A4-4223-B7C8-D3E35E28ACE0Q38604626-A46F2328-1457-48B1-8B08-C495CA2D585AQ38767557-5B684DD9-ACCD-4E47-A44B-7D3FACB58B9FQ38784133-7940F5AA-8030-4A0B-9D58-E5B9BD124DD2Q38828174-49641689-2C1D-4F07-BA11-681FE995B37AQ38883211-C83789C7-E868-43D0-A6EE-8F24432C86A9Q38912064-43A4840A-8766-430B-97B6-22B7B2CBF9B1Q38937725-22D78E80-8FE6-4252-82B3-075C28D08DA1Q39475869-000F9EC0-A002-42CD-9567-99BBBFC9FB63Q40185654-A5599D03-0204-4B8E-A007-FEF282A08AD1Q41975229-55D32C85-7FE4-4040-9F3A-69AACDAFDC37Q42375640-D4325660-8177-4D50-AE9E-279765B0988CQ44051815-17D4E941-B92D-4F26-B52C-6FA5FE02D81BQ44122887-BF184EF2-F680-4742-8D35-4DD6BD396E91Q45854919-D451AB4D-3557-442E-9E1C-48C5EBE43007Q45861918-D38E6EC0-E3E1-4D2A-A2E8-0E0529754071Q45865134-28B93E68-1BB7-47BA-96D5-02C72C17B2D3Q45873013-B003893D-01A7-4B8C-9377-100B3B1A7461Q45875490-F41FF622-4DD1-40C2-A316-83A10B068877Q49745450-B97D29AA-397D-4165-BC66-3F0050E29095Q54958581-E58D1000-B945-4400-B399-51BC413900C3Q58761664-E7424778-277B-476B-9021-0B9476F75F8C
P2860
PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
PEGylated therapeutic proteins ...... ew for haemophilia caregivers.
@en
type
label
PEGylated therapeutic proteins ...... ew for haemophilia caregivers.
@en
prefLabel
PEGylated therapeutic proteins ...... ew for haemophilia caregivers.
@en
P2093
P2860
P1433
P1476
PEGylated therapeutic proteins ...... iew for haemophilia caregivers
@en
P2093
L A Michaels
T A McDonald
T J Humphries
P2860
P356
10.1111/J.1365-2516.2012.02931.X
P50
P577
2012-08-23T00:00:00Z